Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide.
作者信息
Chowdhury Onima, O'Sullivan Jennifer, Barkas Nikolaos, Wang Guanlin, Buck Gemma, Hamblin Angela, Tefferi Ayalew, Al-Ali Haifa K, Barosi Giovanni, Devos Timothy, Gisslinger Heinz, Jiang Qian, Kiladjian Jean-Jacques, Mesa Ruben, Passamonti Francesco, Ribrag Vincent, Schiller Gary, Vannucchi Alessandro M, Zhou Daobin, McMullin Mary Frances, Zhong Jianhua, Gale Robert Peter, Mead Adam J
机构信息
NIHR Biomedical Research Centre and MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
Mayo Clinic, Rochester, MN, USA.
出版信息
Leukemia. 2021 Apr;35(4):1197-1202. doi: 10.1038/s41375-020-0979-6. Epub 2020 Aug 7.
Abstract
摘要
相似文献
1
Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide.
Leukemia. 2021 Apr;35(4):1197-1202. doi: 10.1038/s41375-020-0979-6. Epub 2020 Aug 7.
2
A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence.
Leukemia. 2017 Apr;31(4):896-902. doi: 10.1038/leu.2016.300. Epub 2016 Oct 24.
3
Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis.
Leukemia. 2017 Apr;31(4):889-895. doi: 10.1038/leu.2016.299. Epub 2016 Oct 24.
4
Effect of Red Blood Cell Transfusion Dependence on the Natural History of Myeloproliferative Neoplasm-Associated Myelofibrosis.
Clin Lymphoma Myeloma Leuk. 2015 Nov;15(11):e151-6. doi: 10.1016/j.clml.2015.09.001. Epub 2015 Sep 21.
5
Use of the Functional Assessment of Cancer Therapy--anemia in persons with myeloproliferative neoplasm-associated myelofibrosis and anemia.
Clin Ther. 2014 Apr 1;36(4):560-6. doi: 10.1016/j.clinthera.2014.02.016. Epub 2014 Mar 14.
6
[Transfusion independence achieved with pomalidomide therapy in a patient with primary myelofibrosis].
Rinsho Ketsueki. 2018;59(3):323-325. doi: 10.11406/rinketsu.59.323.
7
A phase-2 trial of low-dose pomalidomide in myelofibrosis.
Leukemia. 2011 Feb;25(2):301-4. doi: 10.1038/leu.2010.254. Epub 2010 Nov 5.
8
Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis.
Leukemia. 2021 Jan;35(1):1-17. doi: 10.1038/s41375-020-0954-2. Epub 2020 Jul 9.
9
Modest activity of pomalidomide in patients with myelofibrosis and significant anemia.
Leuk Res. 2013 Nov;37(11):1440-4. doi: 10.1016/j.leukres.2013.07.007. Epub 2013 Jul 25.
10
[Research status and challenges of advanced myeloproliferative neoplasms].
Zhonghua Yi Xue Za Zhi. 2023 Dec 5;103(45):3603-3607. doi: 10.3760/cma.j.cn112137-20231007-00649.
引用本文的文献
1
Clinical Characteristics and Outcomes of Patients with Primary and Secondary Myelofibrosis According to the Genomic Classification Using Targeted Next-Generation Sequencing.
Cancers (Basel). 2023 Jul 31;15(15):3904. doi: 10.3390/cancers15153904.
2
Impact of Molecular Biology in Diagnosis, Prognosis, and Therapeutic Management of -Negative Myeloproliferative Neoplasm.
Cells. 2022 Dec 27;12(1):105. doi: 10.3390/cells12010105.
3
Genetic Background of Polycythemia Vera.
Genes (Basel). 2022 Apr 2;13(4):637. doi: 10.3390/genes13040637.
4
Philadelphia-Negative MPN: A Molecular Journey, from Hematopoietic Stem Cell to Clinical Features.
Medicina (Kaunas). 2021 Sep 30;57(10):1043. doi: 10.3390/medicina57101043.
5
Impact of Mutational Profile on the Management of Myeloproliferative Neoplasms: A Short Review of the Emerging Data.
Onco Targets Ther. 2020 Dec 1;13:12367-12382. doi: 10.2147/OTT.S287944. eCollection 2020.
Zotero 插件